Navigation Links
Vasopressin (AVP) RIA Test

ProductsVasopressin (AVP) RIA Test
Company Diagnostic Systems Laboratories, Inc.
Item Vasopressin (AVP) RIA Test
Features 
Description Arginine vasopressin (AVP), also known as Antidiurectic Hormone (ADH), is synthesized in the hypothalamus and is transported via exonal flow to the posterior pituitary for storage and eventual release. AVP secretion is regulated by changes in blood osmolality and also by baroreceptors that respond to alterations in blood volume or arterial pressure. Non-osmotic stimuli include pain, stress, sleep and exercise [1]. The primary function of AVP is the regulation of water permeability of the renal collecting tubules and ascending loop of Henle. Mediated through activation of cAMP, the effect of AVP is to allow the kidney to reabsorb water and concentrate urine [1]. At high plasma concentrations, AVP induces a generalized vasoconstriction that leads to a rise in arterial blood pressure. A deficiency in AVP secretion or action is a characteristic of polyuria, a condition in which the renal tubules fail to reabsorb solute-free water. In contrast, sustained, elevated levels of AVP in the absence of any known stimuli are observed in syndrome of inappropriate antidiuretic hormone (SIADH) and can result from a number of factors including secretion of AVP by malignancy, disorders of the central nervous or pulmonary systems, or as a side effect to certain drug therapies.

  1. Whitley RJ, et al. Endocrinology. IN Burtis CA & Ashwood ER (eds). Tietz Textbook of Clinical Chemistry, 2nd ed. WB Saunders Company, Philadelphia, 1994. ch 35, pg 1685-1689.
Info Diagnostic Systems Laboratories, Inc.
Customer Service: (800) 231-7970
Web site: http://www.dslabs.com

Related medicine products :

1. Arginine Vasopressin (AVP, Antidiuretic Hormone, ADH)
2. Arginine Vasopressin Hormone
3. Vasopressin
Solid 8 mm blades. Dull finish. Most popular size or model....
Open 10 mm blades. Dull finish....
Open 14 mm blades of heavy 1 mm wire. Dull finish. Most popular size or model....
Fenestrated 14 mm blades. Self-locking mechanism. Dull finish....
Medicine Products:
(Date:6/22/2017)... ... June 23, 2017 , ... ... fight against hunger on June 21, 2017, at the Emeryville Center of Community ... and malnutrition around the world. , Rise Against Hunger (formerly Stop Hunger Now) ...
(Date:6/20/2017)... MA (PRWEB) , ... June 20, 2017 , ... ... and CHRISTUS Health, a Texas-based health system, will present how predictive analytics drive ... annual HFMA ANI meeting in Orlando, June 25-28. , “The traditional approach ...
(Date:6/20/2017)... ... 2017 , ... After months of negotiations, FaceCradle USA is proud to announce the debut of ... , “Introducing our product on QVC is something we all worked hard to achieve for ... more than 90 million homes in the United States,” said FaceCradle USA President Dylan Doherty. ...
(Date:6/20/2017)... ... June 20, 2017 , ... Hayes, Inc., a leading provider ... titled “ 5 Questions to Ask Before Entering the Maze of Genetic Testing ... Evaluation (GTE) team, the book explores the various types of the more than ...
(Date:6/20/2017)... ... June 20, 2017 , ... Kenneth Mayer, MD, has been appointed ... , Dr. Mayer, who joined the JIAS Editorial Board in 2016, has co-authored more ... Director of Fenway Health and Co-Chair of The Fenway Institute, a member ...
Breaking Medicine News(10 mins):
(Date:6/8/2017)... , June 8, 2017  Less than a ... hit more than 200,000 companies, including hospital networks, in ... heralded as one of the largest online extortion attempts ... the healthcare market, it is imperative that providers understand ... their data from this — and many other very ...
(Date:6/7/2017)... 7, 2017  Novavax, Inc., (Nasdaq: NVAX ) ... 2 trials of its RSV F protein recombinant nanoparticle vaccine ... have been published in the journal Vaccine ... in prior scientific conferences). The Company previously announced top ... is developing the RSV F Vaccine with the goal of ...
(Date:6/3/2017)... June 3, 2017  Eli Lilly and Company ... results from the Phase 3 MONARCH 2 study ... 6 inhibitor, in combination with fulvestrant, significantly improved ... alone in women with hormone-receptor-positive (HR+), human epidermal ... who have relapsed or progressed after endocrine therapy ...
Breaking Medicine Technology: